2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents
Bewersdorf J, Shallis R, Sharon E, Park S, Ramaswamy R, Roe C, Irish J, Caldwell A, Wei W, Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev N, Halene S, Little R, Piekarz R, Gore S, Kim T, Zeidan A. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Annals Of Hematology 2023, 103: 105-116. PMID: 38036712, DOI: 10.1007/s00277-023-05552-4.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsHistone Deacetylase InhibitorsHumansLeukemia, Myeloid, AcuteMyelodysplastic SyndromesConceptsDose-limiting toxicityAcute myeloid leukemiaMarrow complete remissionPhase Ib trialAdverse eventsIb trialDose escalationNCI Cancer Therapy Evaluation ProgramAcute myeloid leukemia refractoryHematologic adverse eventsProtocol-defined responseDose level 1Anti-PD1 therapyAnti-PD1 antibodyDose-escalation designLimited clinical efficacySystems immunology approachHistone deacetylase inhibitor entinostatLeukemia refractoryMCR patientsComplete remissionRespiratory failureSuppressor cellsEscalation designClinical efficacyA randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
Garcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, Rizzieri D, Marcucci G, Strickland S, Litzow M, Savoie M, Medeiros B, Sekeres M, Lin T, Uy G, Powell B, Kolitz J, Larson R, Stone R, Claxton D, Essell J, Luger S, Mohan S, Moseley A, Appelbaum F, Erba H. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia 2023, 38: 58-66. PMID: 37935977, DOI: 10.1038/s41375-023-02073-x.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCytarabineDaunorubicinHumansIdarubicinLeukemia, Myeloid, AcuteRemission InductionVorinostatConceptsHigh-dose cytarabineAcute myeloid leukemiaDose cytarabineRandomized phase III studyUnfavorable-risk cytogeneticsRandomized multicenter trialOverall remission ratePhase III studyHigh response rateHistone deacetylase inhibitorsInduction therapyFree survivalPrimary endpointRemission rateUntreated patientsIII studyOverall survivalYounger patientsMulticenter trialImproved outcomesMyeloid leukemiaCytogenetic subsetsCytarabineResponse rateHigh dosesGilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
Pratz K, Cherry M, Altman J, Cooper B, Podoltsev N, Cruz J, Lin T, Schiller G, Jurcic J, Asch A, Wu R, Hill J, Gill S, James A, Rich E, Hasabou N, Perl A, Levis M. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. Journal Of Clinical Oncology 2023, 41: 4236-4246. PMID: 37379495, DOI: 10.1200/jco.22.02721.Peer-Reviewed Original ResearchMeSH KeywordsAdultConsolidation ChemotherapyFms-Like Tyrosine Kinase 3HumansIdarubicinLeukemia, Myeloid, AcuteMutationNeoplasm Recurrence, LocalProtein Kinase InhibitorsConceptsPhase Ib studyMaintenance therapyConsolidation chemotherapyDose escalationFLT3 inhibitorsIb studyHigh-dose cytarabine consolidationMedian overall survival timeSingle-agent maintenance therapyComplete response rateHigher trough levelsOverall survival timeCytarabine consolidationChemotherapy regimenDose expansionAdult patientsIntensive inductionTrough levelsCount recoveryMedian timeRandomized trialsInduction cyclesSurvival timeDay 1Response rateSupportive Care for Patients With Myelodysplastic Syndromes
Stempel J, Podoltsev N, Dosani T. Supportive Care for Patients With Myelodysplastic Syndromes. The Cancer Journal 2023, 29: 168-178. PMID: 37195773, DOI: 10.1097/ppo.0000000000000661.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBlood TransfusionChemopreventionCOVID-19HumansIron OverloadLeukemia, Myeloid, AcuteMyelodysplastic SyndromesPalliative CareConceptsMyelodysplastic syndromeMyeloid leukemiaLow-risk diseaseTreatment-related complicationsSupportive care interventionsSupportive care measuresAcute myeloid leukemiaBone marrow disordersAntimicrobial prophylaxisFrequent complicationProgressive cytopeniasSupportive careTransfusion supportHigh-risk counterpartsBetter prognosisPalliative careRoutine immunizationCare measuresCare interventionsIneffective hematopoiesisIron overloadCommon causeMarrow disordersSyndrome populationPatientsImpact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome
Allen C, Gautam S, Cheng W, Pine A, Podoltsev N, Zeidan A, Lee A, Shallis R. Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome. Acta Haematologica 2023, 146: 287-292. PMID: 37166332, DOI: 10.1159/000530153.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultHumansLeukemia, Myeloid, AcuteMyelodysplastic SyndromesRetrospective StudiesConceptsAML/myelodysplastic syndromeAcute myeloid leukemiaInternational normalized ratioAntibacterial prophylaxisMyelodysplastic syndromeProphylactic antibacterialsCoagulation profileAcute myeloid leukemia/myelodysplastic syndromeDiagnosis of AMLHigher international normalized ratioLeukemia/myelodysplastic syndromePartial thromboplastin time prolongationYale-New Haven HospitalYale-New HavenRetrospective cohort studyAbnormal coagulation profileGroup of patientsTime of admissionHigh rateIndividual patient encountersInstitutional review boardAntibacterial exposureRelevant bleedingAdult patientsCohort studySecond malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosis
2022
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Perl A, Larson R, Podoltsev N, Strickland S, Wang E, Atallah E, Schiller G, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon S, Maeda Y, Hosono N, Onozawa M, Kato T, Kim H, Hasabou N, Nuthethi R, Tiu R, Levis M. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplantation And Cellular Therapy 2022, 29: 265.e1-265.e10. PMID: 36526260, PMCID: PMC10189888, DOI: 10.1016/j.jtct.2022.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAniline CompoundsFms-Like Tyrosine Kinase 3HumansLeukemia, Myeloid, AcuteRecurrenceConceptsHematopoietic stem cell transplantationAcute myelogenous leukemiaPost-transplantation maintenance therapyLower relapse rateAdverse eventsADMIRAL trialMaintenance therapyPost-transplantation survivalGilteritinib armRelapse rateSalvage chemotherapyMyelogenous leukemiaRefractory acute myelogenous leukemiaTreatment-emergent adverse eventsFLT3 internal tandem duplication (ITD) mutationsCommon adverse eventsComposite complete remissionGlobal phase 3Incidence of gradePost-transplantation complicationsTransplantation-eligible patientsAlanine aminotransferase levelsHigher remission ratesOverall survival rateSurvival of patientsCost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stein E, Huntington S, Zeidan A. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. Leukemia & Lymphoma 2022, 64: 454-461. PMID: 36493798, PMCID: PMC9957935, DOI: 10.1080/10428194.2022.2140288.Peer-Reviewed Original ResearchMeSH KeywordsAzacitidineCost-Benefit AnalysisHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcutePyridinesQuality-Adjusted Life YearsUnited StatesFollow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 2022, 139: 3366-3375. PMID: 35081255, PMCID: PMC9197557, DOI: 10.1182/blood.2021011583.Peer-Reviewed Original ResearchMeSH KeywordsAniline CompoundsFms-Like Tyrosine Kinase 3Follow-Up StudiesHumansLeukemia, Myeloid, AcuteMutationPyrazinesRecurrenceConceptsAcute myeloid leukemiaSalvage chemotherapyADMIRAL trialSC armOverall survivalFLT3 mutation-positive acute myeloid leukemiaPositive acute myeloid leukemiaComposite complete remissionStable safety profileAdverse event incidenceCommon adverse eventsLiver transaminase levelsMedian overall survivalSuperior overall survivalLong-term treatment effectsGilteritinib armComplete remissionMaintenance therapyAdverse eventsCumulative incidenceMedian survivalTransaminase levelsEvent incidenceMaintenance treatmentSafety profileClinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, Recher C, Smith CC, Levis MJ, Strickland S, Röllig C, Groß-Langenhoff M, Chou WC, Lee JH, Yokoyama H, Hasabou N, Lu Q, Tiu RV, Altman JK. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal 2022, 12: 84. PMID: 35637252, PMCID: PMC9151663, DOI: 10.1038/s41408-022-00677-7.Peer-Reviewed Original ResearchMeSH KeywordsAniline CompoundsFms-Like Tyrosine Kinase 3HumansLeukemia, Myeloid, AcuteMutationProtein Kinase InhibitorsPyrazinesRetrospective StudiesSorafenibStaurosporineConceptsAcute myeloid leukemiaFLT3-TKIRefractory FLT3TKI exposureSalvage chemotherapyClinical outcomesMyeloid leukemiaR AMLLonger median overall survivalComposite complete remissionHigher CRCS ratesMedian overall survivalTyrosine kinase inhibitor midostaurinKinase inhibitor midostaurinPotential clinical impactADMIRAL trialCRC ratesGilteritinib armPrior sorafenibComplete remissionRemission durationOverall survivalTKI therapyTKI useSurvival outcomesCost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia
Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Podoltsev NA, Huntington SF, Zeidan AM. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood 2022, 139: 1766-1770. PMID: 35298594, PMCID: PMC8931513, DOI: 10.1182/blood.2021014401.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesCost-Benefit AnalysisCytarabineDaunorubicinHumansLeukemia, Myeloid, AcutePractice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
Bewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.Peer-Reviewed Original ResearchMeSH KeywordsHospital MortalityHumansLeukemia, Myeloid, AcuteLeukemia, Promyelocytic, AcuteMiddle AgedOdds RatioPrognosisUnited StatesConceptsAcute promyelocytic leukemiaAdverse outcomesPromyelocytic leukemiaNational Comprehensive Cancer Network guidelinesBaseline white blood cell countFavorable long-term prognosisWhite blood cell countVizient Clinical Data BaseGuideline-concordant regimensGuideline-concordant therapyGuideline-concordant treatmentGuideline-recommended therapiesBaseline clinical characteristicsHigh-risk diseaseLong-term prognosisPopulation-based registryBlood cell countClinical data baseLarge database analysisLogistic regression modelsTreatment concordanceClinical characteristicsReal-world practiceTreatment patternsNetwork guidelines
2021
Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy
Shallis RM, Pucar D, Perincheri S, Gore SD, Seropian SE, Podoltsev NA, Zeidan AM. Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. Annals Of Hematology 2021, 101: 1145-1147. PMID: 34686913, DOI: 10.1007/s00277-021-04702-w.Peer-Reviewed Case Reports and Technical NotesHypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.Peer-Reviewed Original ResearchMeSH KeywordsFms-Like Tyrosine Kinase 3Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMyelodysplastic SyndromesProtein Kinase InhibitorsConceptsAcute myeloid leukemiaRelapse-free survivalMaintenance therapyMyelodysplastic syndromeFLT3 inhibitorsAllo-HCTHazard ratioMaintenance treatmentClinical trialsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationControl groupSystematic reviewAllogeneic hematopoietic cell transplantMeasurable residual disease statusHematopoietic stem cell transplantationMeasurable residual disease testingNon-relapse mortalityHematopoietic cell transplantPre-emptive treatmentResidual disease statusStem cell transplantationFavorable safety profileSame patient cohortRandom-effects modelVenetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 2021, 62: 3394-3401. PMID: 34477024, PMCID: PMC9012492, DOI: 10.1080/10428194.2021.1966788.Peer-Reviewed Original ResearchMeSH KeywordsBridged Bicyclo Compounds, HeterocyclicHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteRetrospective StudiesSulfonamidesConceptsAcute myeloid leukemiaAllogeneic hematopoietic cell transplantAllo-HCTHematopoietic cell transplantSalvage therapyMyelodysplastic syndromeCell transplantMemorial Sloan-Kettering Cancer CenterHigh-risk myelodysplastic syndromeSecond allo-HCTSalvage treatment optionOverall response rateMedian followMedian OSVenetoclax therapyRetrospective studyCancer CenterTreatment optionsOS estimatesMyeloid leukemiaPatientsResponse rateTherapyTransplantMonthsLaboratory evaluation and prognostication among adults and children with CEBPA‐mutant acute myeloid leukemia
Mendoza H, Podoltsev NA, Siddon AJ. Laboratory evaluation and prognostication among adults and children with CEBPA‐mutant acute myeloid leukemia. International Journal Of Laboratory Hematology 2021, 43: 86-95. PMID: 34288448, DOI: 10.1111/ijlh.13517.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCEBPA mutant acute myeloid leukemiaAcute myeloid leukemiaCEBPA mutationsMyeloid leukemiaLeukemogenic mutationsPositive prognostic impactSingle CEBPA mutationsSimilar survival outcomesNegative prognostic effectFLT3-ITD mutationLaboratory evaluationWild-type CEBPAMultiparameter flow cytometryGermline CEBPA mutationsFavorable prognosisPrognostic impactMutation presencePrognostic effectRisk stratificationSurvival outcomesGATA2 mutationsDistinct subtypesMolecular findingsCEBPA geneFlow cytometryA Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia
Daver N, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia. American Journal Of Hematology 2021, 96: e175-e179. PMID: 33617672, PMCID: PMC8252033, DOI: 10.1002/ajh.26136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodiesAntineoplastic AgentsChemical and Drug Induced Liver InjuryDose-Response Relationship, DrugEarly Termination of Clinical TrialsFemaleHumansImmunoconjugatesLectins, C-TypeLeukemia, Myeloid, AcuteMaleMiddle AgedMutationNeoplasm ProteinsNeoplasms, Second PrimaryReceptors, MitogenYoung AdultCost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
Patel KK, Zeidan AM, Shallis RM, Prebet T, Podoltsev N, Huntington SF. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Advances 2021, 5: 994-1002. PMID: 33591323, PMCID: PMC7903235, DOI: 10.1182/bloodadvances.2020003902.Peer-Reviewed Original ResearchMeSH KeywordsAgedAzacitidineBridged Bicyclo Compounds, HeterocyclicCost-Benefit AnalysisHumansLeukemia, Myeloid, AcuteSulfonamidesConceptsUntreated acute myeloid leukemiaIncremental cost-effectiveness ratioAcute myeloid leukemiaUnfit patientsMyeloid leukemiaLifetime health care costsSignificant price reductionUntreated AML patientsOverall survival curvesUS payer perspectiveCost-effectiveness ratioParametric survival modelingHealth care costsPrice reductionIntensive chemotherapyOverall survivalAML patientsTreatment strategiesCurrent pricingResponse rateCare costsSurvival curvesVenetoclaxClinical settingAzacitidine
2020
Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission.
Shallis RM, Podoltsev NA. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. Current Opinion In Hematology 2020, 28: 110-121. PMID: 33394722, DOI: 10.1097/moh.0000000000000637.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorClinical Decision-MakingCombined Modality TherapyDisease ManagementDisease SusceptibilityHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaintenance ChemotherapyRandomized Controlled Trials as TopicRemission InductionTreatment OutcomeConceptsAcute myeloid leukemiaMaintenance therapyMeasurable residual diseaseMyeloid leukemiaOral hypomethylating agentPost-transplant settingImmune checkpoint inhibitorsPlacebo-controlled trialHigh-risk diseaseAML patient populationRecent positive findingsMRD statusSustained remissionCheckpoint inhibitorsAML patientsRandomized trialsResidual diseasePatient populationHypomethylating agentMRD techniquesTherapyPositive findingsPatientsBcl-2RemissionA case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance
Mendoza H, Chen PH, Pine AB, Siddon AJ, Bale AE, Gowda L, Killie A, Richards J, Varin-Tremblay C, Kloss R, Podoltsev NA. A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance. Leukemia & Lymphoma 2020, 62: 1251-1254. PMID: 33345654, DOI: 10.1080/10428194.2020.1861276.Peer-Reviewed Case Reports and Technical NotesCCAAT-Enhancer-Binding ProteinsGerm CellsGerm-Line MutationHumansLeukemia, Myeloid, AcuteMutationPenetrancePrognosis